Healthcare professionals working in hospitals are likely to care for people in their last year of life. Many of these people will be older, frail and at high risk of adverse events. The management of medicines forms a large part of the care of this population. The interdisciplinary healthcare team can identify patients who are near the end of their life and, in partnership with the patient (or substitute decision maker) and family, plan to achieve their goals of care. Pharmacists can contribute to quality outcomes through their specialist knowledge of the unique medication issues at the end of life. This is particularly important in the context of the frail older person with comorbidities that may complicate medication management. Effective medication management and team collaboration can relieve suffering and bring comfort to the dying patient and their family. This article outlines considerations for hospital-based clinicians treating the older person approaching the end of their life.
INTRODUCTION
Palliative care is an approach that strives to maintain the quality of life of people living with a life-limiting illness and their families. 1 It can be defined narrowly as the services provided around the immediate time of death, or broadly as the approach adopted once it is clear that a health condition is likely to lead to death in the relatively near future. 1 Palliative care aims to prevent and relieve suffering through early identification and assessment, as well as the treatment of pain and other problems -physical, psychosocial and spiritual. 1 Recent estimates suggest there are approximately 100 000 Australians annually needing support from specialist palliative care services, with most of these admitted to an acute care hospital at least once in the last year of their life. 2, 3 Furthermore, approximately half of all deaths occur in the acute hospital setting. 4 To put this in context, a South Australian study suggests that, at any point in time, one-third of acute hospital inpatients warrant a palliative approach to their care, with only one-fifth of these having input from a specialist palliative care service. 5 Recognition of these needs led the Australian Commission on Safety and Quality in Health Care (ACSQHC) to develop the National Consensus Statement: Essential Elements for Safe High Quality End of Life Care and incorporate end-of-life care in the second edition of the National Safety and Quality Health Service Standards. 6, 7 Many older hospital inpatients approaching the end of their life are frail, suffering from multimorbidity and dying from one or more chronic diseases. Caring for this group presents a number of challenges and complexities, including prognostication, advance care planning, assessment of the patient's decision-making capacity and managing comorbid illness and polypharmacy.
The interdisciplinary team, including pharmacists, has a key role in the care of people approaching the end of life and requires core knowledge, skills, resources and supports. In this article we outline considerations for hospital-based clinicians treating the older person approaching the end of their life.
THE LAST YEAR OF LIFE
Recognising when people are in the last year of life assists with the planning and management of their care for the remaining months of their life. When the person reaches the last days to weeks of life, this is referred to as the terminal phase. Prognostication of survival in the multimorbid, frail older person is not an exact science and can be challenging even for the most experienced clinician. There are tools that can be used to identify people approaching the end of their life. The Supportive and Palliative Care Indicators Tool (SPICT) helps identify people at high risk of deterioration and dying, who are often at the end of life, and includes a combination of general and specific indicators. 8 Another simple tool, the 'surprise question' ('Would I be surprised if this patient died in the next 12 months?'), has similar utility in identifying people with palliative care needs. 9 The identification that someone is approaching the end of their life should trigger a number of considerations from the clinical team.
Advance Care Planning
Advance care planning is a process of planning for future health and personal care, whereby the person's values and preferences are made known so that they can guide decision making at a future time when the person cannot make or communicate their decisions. 5 These discussions can articulate a person's goals of care, preferences for treatment, including treatment limitations, and their choice of substitute decision makers for the future. Clear documentation in an advance care plan (ACP) supports these discussions for future reference. Given the risk of deterioration at the end of life and the high incidence of cognitive impairment, including delirium and dementia, ACPs are important in the older population.
Review of Medicines for Long-Term Comorbidities
Many older people have multiple chronic diseases and associated polypharmacy. 10 As they approach the end of life, it is timely to review medicines. 11 Medicines used for preventative purposes (e.g. statins for secondary prevention of vascular events) change their benefit : risk profile as life expectancy shortens. Although studies are often lacking, given the vulnerability of frail older people to iatrogenic harm, it is likely that the number needed to treat for benefit increases and the number needed to harm decreases. Therefore, long-term preventative treatments should be reviewed and cessation considered according to the person's goals. In addition, changing health states as patients approach the end of life may affect their continuing need for particular medicines. For example, significant weight loss associated with advanced disease may improve blood pressure or hyperglycaemic control, meaning antihypertensives or oral hypoglycaemic agents that were previously required may now be causing problematic hypotension or hypoglycaemia.
Changes in hepatic and renal function may affect the metabolism and elimination of medicines. For example, deteriorating renal function may lead to the accumulation of and toxicity from medicines, such as hypoglycaemia from sulfonylureas and excessive bleeding from oral anticoagulants.
Reducing medicines may help with adherence and reduce risks of drug-drug interactions, adverse drug reactions and other adverse outcomes, such as oversedation and falls. 12 Simplifying medication regimens is also important where the medicines are managed by the carer. Deprescribing, or cessation of medicines, must take into consideration whether there may be a withdrawal or discontinuation syndrome associated with abrupt cessation (e.g. some serotonin reuptake inhibitors). Appropriate strategies should be considered, such as gradual withdrawal or medication substitution. Antidiabetic medicines, lipid-lowering medicines and anticoagulants can usually be withdrawn without consequences. 13 Consensus-derived recommendations exist to help guide decisions about deprescribing in the last year of life, such as the OncPal deprescribing guideline for oncology patients with less than 6 months remaining life expectancy, 14 and the STOPP-Frail (Screening Tool of Older Persons Prescriptions in Frail adults with limited life expectancy) guidelines for older frail individuals with poor 1-year survival prognosis. 15 
TERMINAL PHASE
The terminal phase is typically a period of deterioration led by increasing symptom burden, including fatigue and the inability to swallow. Effective use of medicines is important in maintaining patient comfort during this phase. This must be balanced with the recognition that the older person is more vulnerable to adverse medicine events. Having a thorough medicine history is paramount to anticipating needs and delivering good symptom management.
Diagnosing Dying
One challenge in effective care planning at the end of life is early recognition of dying. Recognition of the terminal phase requires exclusion of potential reversible causes and consideration of the appropriateness of investigations and the wishes of the patient. If the recognition of dying is missed or delayed, the opportunity to support shared decision making and to plan care through careful conversations with the patient and family can be missed. This may lead to inappropriate and futile treatments, including overuse of medical emergency teams for the management of clinical deterioration in hospital. 16 Unnecessary suffering can result, with poor and sometimes traumatic experiences for the patient and family, with potential for consequential effects on bereavement.
17,18
Reassessing Goals of Care
The terminal phase is an opportunity to reassess care needs and review the goals of care. In the hospital setting, the treating team needs to ensure care is provided according to previous guidance from the patient if they are now unable to give direction. Older people may have impaired capacity to make decisions as they approach the terminal phase due to impairment of cognition, including from delirium, dementia, cerebral damage (e.g. stroke) or adverse effects of medicines (e.g. the effects of opiates). An ACP may guide management and identify a prearranged substitute decision maker to discuss the person's preferences. An ACP can also relieve substitute decision makers of some of the stress associated with making difficult decisions at this emotional time.
Managing Acute Symptoms
In most people entering the terminal phase, anticipated symptoms include pain, dyspnoea, nausea, terminal restlessness and noisy breathing. 19 These may result from changes in physiology as the body shuts down or changes in the underlying illness. As patients approach death, dysphagia is common and often parenteral medicines are required. Commonly, the subcutaneous route is used for ease of access, efficacy and safety compared with other routes, such as intravenous. This may involve:
• converting existing oral medicines to subcutaneous formulations • adding new subcutaneous medicines for the management of symptoms
• prescribing new subcutaneous medicines in anticipation of symptoms ('anticipatory prescribing').
Anticipatory prescribing facilitates prompt symptom control by initiating orders for appropriate medicines in anticipation of the symptoms arising. Thus, when the person requires medicines, they can be given immediately, avoiding delays through having to contact prescribers, obtain orders and access the medicine. Inadequately controlled symptoms in the terminal phase can lead to unnecessary stress and escalation of care.
For many health providers, care for people in the terminal phase will constitute only a small component of their workload; therefore, having a suite of resources to help them prescribe medicines in this vulnerable population is important. 
Altered Pharmacokinetics
For the frail older patient, further consideration is required when prescribing, given the side effect profiles of medicines and the effect of organ dysfunction (examples are given in Boxes 1, 2).
With the rising popularity of oxycodone and naloxone combination formulations, it is worth noting that for people at the end of life there are case reports of significant inhibition of oxycodone by systemically absorbed naloxone in patients with hepatic impairment. 20 This can lead to a lack of benefit from combination products containing naloxone, or opiate toxicity when using equipotent tables to switch to other opioids.
Opioids and Dose Conversion
Dose conversion tables and calculators are useful for patients on stable doses of oral opioids when there is a need to switch to a different opioid or to parenteral administration. Table 2 lists a range of opioid conversion tools. Using one resource consistently will ensure familiarity. Because conversion ratios are based on averages, there will be differences in how patients respond and between tools. Reducing the final calculated dose by up to 50%, to allow for interindividual variations in conversion, will ensure that the frail older patient is switched safely. Prescribing breakthrough doses for opioids will ensure the person is comfortable; these should be calculated as one-sixth to one-tenth of the daily background opioid dose.
14 Breakthrough doses should be prescribed up to every hour, as required. Initiating transdermal opioids in the terminal phase is inadvisable due to inconsistent transdermal absorption and the delay in onset of effect with any change or titration. However, it may be suitable to leave an existing transdermal patch in place, using the subcutaneous route for administering additional background or breakthrough doses.
Syringe Drivers
Syringe drivers are used to administer medicines continuously via the subcutaneous route. 
Box 2 Selecting Anticholinergics for the Management of Noisy Breathing
Pharmacological management options are limited to the use of anticholinergics to prevent respiratory secretions forming. The evidence supporting the routine use of anticholinergics is limited; the most robust head-to-head study showed no difference in effect comparing three different anticholinergics. However, there was no placebo arm to understand the natural evolution of symptoms. 30 That study also suggested using anticholinergics early, rather than later. Despite the limited supporting evidence, anticholinergics are frequently prescribed. Atropine and hyoscine hydrobromide cross the blood-brain barrier and can contribute to sedation and delirium. Conversely, hyoscine butylbromide and glycopyrrolate do not cross the blood-brain barrier and thus avoid central nervous system effects.
Box 1 Using Opioids in People with Renal Impairment
Subcutaneous morphine remains the gold standard in the management of pain in the terminal phase; it is clinically comparable to other opioids, widely available, familiar for prescribers and inexpensive. 28 For the frail elderly patient with moderate to severe renal impairment, many clinicians prescribe oxycodone or fentanyl. These lack the neurotoxic metabolites that accumulate with morphine. with a long half-life (e.g. clonazepam) separately, as a subcutaneous bolus once or twice a day. Where prescribers or nurses are uncertain about how to approach incompatible medicines, discussion with the pharmacist or the local specialist palliative care service is recommended.
Withdrawing Medicines Abruptly
The loss of the oral route may preclude a planned withdrawal of some medicines. When abruptly ceasing long-term medicines that can precipitate withdrawal reactions (e.g. anticonvulsants, antihypertensives and antidepressants), consider the repercussions and anticipate using subcutaneous medicines to limit the discomfort associated with rapid withdrawal (e.g. agitation), or rebound effects. 23 For some medicines, such as adjuvant analgesics, there may be no subcutaneous formulation available to convert to, thus creative ways to ensure the symptom management will be needed.
Transitions to the Community
For patients transitioning from the hospital setting to home or to a residential aged care facility, prescribers and pharmacists have a critical role in facilitating symptom control on discharge and ensuring ongoing medication supplies are available in the community. This may include liaising with the patient's preferred community pharmacy. Medicines should be prescribed and supplied at discharge from hospital, rather than leaving this for the patient's general practitioner and community pharmacy to arrange. For patient convenience and cost, it is prudent to consider availability through the Australian Pharmaceutical Benefits Schedule (see example in Box 3). Although the community pharmacy is well placed to provide medicines for symptom control in the terminal phase, urgently accessing subcutaneous medicines in the community can be challenging. 24 Contingencies should be in place for carers to access ongoing supplies of medicines in the event that symptoms escalate, or the terminal phase lasts longer than expected. This may include supplying larger quantities upon discharge or informing the person's local community pharmacy of likely needs. Clear communication with community providers (such as the specialist palliative care service and the person's general practitioner) is paramount.
SUPPORTING THE PERSON AND THEIR CARER
It is important to ensure that patients and their carers have a good understanding of the problems that may arise as the end of life approaches. Good communication can proactively manage their expectations and reassure them that situations can be managed. Carers are critical in the support of their loved one's ability to remain at home as function declines. They play a considerable role in providing good symptom control because they may be responsible for procuring, administering and monitoring medicines. Including carers in discussions when planning to discharge their loved one from hospital will prepare them for issues that may present once home.
Supports such as home nursing can be arranged, but family carers usually retain a significant role in managing medicines in the terminal phase. Reassurance and written plans instructing when and how carers manage breakthrough symptoms are paramount. The Caring Safely At Home project has developed a number of freely available resources, including videos and fact sheets, to support carers to administer medicines in the home environment. Care for the older dying patient in the hospital For many, the experience of seeing someone they love deteriorate is new and they are likely to have many questions. Ensuring they know who to call for help, taking the time to discuss their concerns around changes to their loved one's medicines and advocating where appropriate contributes to trust building. Good communication skills, such as asking what they understand about the situation, can be used to encourage conversation, build trust and assess their knowledge of what is happening, thus influencing the person's family and carer's experience of the death.
The published literature describes how family members need health providers to explain the significance of clinical signals, such as deteriorating function, in clear and direct language. 26 Poor communication at key points is a major contributor to the perception of poor quality of care at the end of life and poor bereavement outcomes. 27 
CONCLUSION
Medication management in vulnerable older people at the end of their life is complex and requires an interdisciplinary approach that places the patient and their families at the centre of care. Importantly, the risks of caring for older people at end of life are known, and strategies can be used to mitigate or prevent harm.
Pharmacists have a key role within the interdisciplinary team, helping ensure the quality of care for people at the end of life. Good-quality systems that span the continuum of care and collaborative team processes are necessary to ensure generalist health providers, including pharmacists, are supported to provide safe, quality care for the frail older person at the end of their life.
